Spyre Therapeutics Inc. (NASDAQ:SYRE) is one of the small-cap stocks that are on fire right now. On April 16, Spyre Therapeutics successfully closed an underwritten public offering, generating ~$463.5 million in gross proceeds. The final total reflects the full exercise of the underwriters’ option to purchase an additional 975,000 shares, bringing the total number of shares of common stock sold to 7,475,000 at a public offering price of $62.00 per share. The company plans to use these funds to further its ...